Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF) (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 9.84% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $12.9 million (up 9.19% YoY), while the FY2025 annual figure was $12.9 million, up 14.28% from the prior year.
• Depreciation & Amortization (CF) eased to $2.8 million in Q1 2026 per IOVA's latest filing, from $3.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.7 million in Q4 2025 and bottomed at $1.8 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 501.09% — and 2025, when it declined 14.33%.
• Iovance Biotherapeutics' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then increased by 4.8% to $2.9 million in 2023, then climbed by 11.05% to $3.3 million in 2024, then rose by 13.71% to $3.7 million in 2025, then fell by 24.19% to $2.8 million in 2026.
• Business Quant data shows IOVA's Depreciation & Amortization (CF) at $2.8 million in Q1 2026, $3.7 million in Q4 2025, and $3.0 million in Q3 2025.